In:
Head & Neck, Wiley, Vol. 41, No. 12 ( 2019-12), p. 4151-4163
Kurzfassung:
The purpose of this study was to investigate significance of HPV16 DNA/p16 for survival of patients with laryngeal squamous cell carcinoma (LSCC). Methods HPV16 DNA and p16 status in 812 LSCC patients were determined. The survival was performed using Kaplan‐Meier estimates and Cox model. Results Compared with HPV negativity, adjusted HRs for HPV16 positivity were 0.57, 95% CI, 0.38 to 0.87; 0.60, 0.40 to 0.88; and 0.65, 0.46 to 0.94 for disease‐specific survival (DSS), recurrence‐free survival (RFS), and overall survival (OS), respectively. Additionally, for p16 expression, aHRs were 0.68, 95% CI, 0.48 to 0.96; 0.72, 0.52 to 0.98; and 0.73, 0.54 to 0.99 for DSS, RFS, and OS, respectively. Finally, for combined analysis, patients with both HPV16‐positivity/p16‐positivity had much better prognosis than those with either negativity. Such above survivals are more significantly better in never smokers. Conclusion Our findings suggest that HPV16/p16 may affect survival outcomes of LSCC patients, particularly in never smokers.
Materialart:
Online-Ressource
ISSN:
1043-3074
,
1097-0347
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2019
ZDB Id:
2001440-5
Permalink